126 related articles for article (PubMed ID: 17110373)
1. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.
Song JJ; An JY; Kwon YT; Lee YJ
J Biol Chem; 2007 Jan; 282(1):319-28. PubMed ID: 17110373
[TBL] [Abstract][Full Text] [Related]
2. [Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer].
Zhu HB; Huang XF; Hu JZ; Zhou W; Chen W; Chen LL; He C
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):245-9. PubMed ID: 18788624
[TBL] [Abstract][Full Text] [Related]
3. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
4. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
5. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
Zhou DH; Yang LN; Roder C; Kalthoff H; Trauzold A
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):94-8. PubMed ID: 23392805
[TBL] [Abstract][Full Text] [Related]
6. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ
Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B
Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072
[TBL] [Abstract][Full Text] [Related]
8. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.
Hinz S; Trauzold A; Boenicke L; Sandberg C; Beckmann S; Bayer E; Walczak H; Kalthoff H; Ungefroren H
Oncogene; 2000 Nov; 19(48):5477-86. PubMed ID: 11114725
[TBL] [Abstract][Full Text] [Related]
9. Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells.
Kim SY; Lee DH; Song X; Bartlett DL; Kwon YT; Lee YJ
Apoptosis; 2014 Nov; 19(11):1603-15. PubMed ID: 25156145
[TBL] [Abstract][Full Text] [Related]
10. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL.
Bansal H; Seifert T; Bachier C; Rao M; Tomlinson G; Iyer SP; Bansal S
J Biol Chem; 2012 Sep; 287(39):32875-80. PubMed ID: 22898820
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
14. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
Lamothe B; Aggarwal BB
J Interferon Cytokine Res; 2002 Feb; 22(2):269-79. PubMed ID: 11911810
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation.
Sonnemann J; Gekeler V; Sagrauske A; Müller C; Hofmann HP; Beck JF
Int J Oncol; 2004 Oct; 25(4):1171-81. PubMed ID: 15375570
[TBL] [Abstract][Full Text] [Related]
16. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B
Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL.
Chi HC; Chen SL; Liao CJ; Liao CH; Tsai MM; Lin YH; Huang YH; Yeh CT; Wu SM; Tseng YH; Chen CY; Tsai CY; Chung IH; Chen WJ; Lin KH
Cell Death Differ; 2012 Nov; 19(11):1802-14. PubMed ID: 22576662
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction.
Petrella A; Ercolino SF; Festa M; Gentilella A; Tosco A; Conzen SD; Parente L
Eur J Cancer; 2006 Dec; 42(18):3287-93. PubMed ID: 17070682
[TBL] [Abstract][Full Text] [Related]
20. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]